- 询价
- 2025年08月19日
14 年金牌会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 技术资料
- 库存：
大量
- 组织来源：
cortex
- 器官来源：
肾上腺
- 运输方式：
冻存运输
- 物种来源：
人
- 是否是肿瘤细胞：
1
- 细胞形态：
上皮样
- 相关疾病：
肿瘤
- ATCC Number：
CRL-2128™
- 年限：
48 years
- 生长状态：
贴壁生长
| Designations: | NCI-H295R [H295R] | ||
| Depositors: | WE Rainey | ||
| Biosafety Level: | 1 | ||
| Shipped: | frozen | ||
| Medium & Serum: | See Propagation | ||
| Growth Properties: | adherent | ||
| Organism: | Homo sapiens | ||
| Morphology: | epithelial |
||
| Source: | Organ: adrenal gland Tissue: cortex Disease: carcinoma |
||
| Cellular Products: | aldosterone; cortisol; C19 steroids | ||
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | ||
| Applications: | It is responsive to angiotensin II and potassium ions. NCI-H295R was adapted from the NCI-H295 pluripotent adrenocortical carcinoma cell line (ATCC CRL-10296 ) established by A.F. Gazdar and associates from a carcinoma of the adrenal cortex. This cell line retains the ability to produce adrenal androgens. |
||
| DNA Profile (STR): | Amelogenin: X CSF1PO: 10,12 D13S317: 13 D16S539: 11 D5S818: 12 D7S820: 9,12 THO1: 9.3 TPOX: 8 vWA: 17,18 |
||
| Age: | 48 years | ||
| Gender: | female | ||
| Ethnicity: | Black | ||
| Comments: | NCI-H295R was adapted from the NCI-H295 pluripotent adrenocortical carcinoma cell line (ATCC CRL-10296 ) established by A.F. Gazdar and associates from a carcinoma of the adrenal cortex. The original cells were adapted to a culture medium which decreased the population doubling time from 5 days to 2 days. While the original cells grew in suspension, the adapted cells were selected to grow in a monolayer. This cell line retains the ability to produce adrenal androgens. It is responsive to angiotensin II and potassium ions. | ||
| Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated DMEM:F12 Medium Catalog No. 30-2006. To make the complete growth medium, add the following components to the base medium: 0.00625 mg/ml insulin; 0.00625 mg/ml transferrin; 6.25 ng/ml selenium; 1.25 mg/ml bovine serum albumin; 0.00535 mg/ml linoleic acid; adjust to a final concentration of 2.5% Nu-Serum I. The additives (insulin, transferrin, selenium, BSA and linoleic acid) are available in the form of ITS+ Premix from BD Biosciences. Nu-Serum is also available from BD Biosciences. Atmosphere: air, 95%; carbon dioxide (CO2), 5% |
||
| Subculturing: | Protocol:
|
||
| Preservation: | Freeze medium: Complete growth medium + extra 7.5% Nu-Serum, 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor phase |
||
| Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2006 parental cell line:ATCC CRL-10296 0.25% (w/v) Trypsin - 0.53 mM EDTA in Hank' BSS (w/o Ca++, Mg++):ATCC 30-2101 Cell culture tested DMSO:ATCC 4-X |
||
| References: | 22400: Rainey WE, et al. The NCI-H295 cell line: a pluripotent model for human adrenocortical studies. Mol. Cell. Endocrinol. 100: 45-50, 1994. PubMed: 8056157 22764: Rainey WE, et al. Regulation of human adrenal carcinoma cell (NCI-H295) production of C19 steroids. J. Clin. Endocrinol. Metab. 77: 731-737, 1993. PubMed: 8396576 23082: Gazdar AF, et al. Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res. 50: 5488-5496, 1990. PubMed: 2386954 23515: Bird IM, et al. Human NCI-H295 adrenocortical carcinoma cells: a model for angiotensin- II-responsive aldosterone secretion. Endocrinology 133: 1555-1561, 1993. PubMed: 8404594 |
||
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
技术资料暂无技术资料 索取技术资料
NCI-H295R
询价
